Extended use of rh-endostatin improves prognosis in patients with advanced non-small cell lung cancer: an analysis of retrospective study

BACKGROUND: Rh-endostatin is a potent inhibitor of angiogenesis approved and widely used for advanced non-small cell lung cancer (NSCLC) in China. While the efficacy and safety of extended use of rh-endostatin with platinum-based chemotherapy during induced and maintenance therapy are still not very...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing, Cheng, Yi, He, Liting, Wang, Jianhua, Xi, Qingsong, Gong, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745542/
https://www.ncbi.nlm.nih.gov/pubmed/36524068
http://dx.doi.org/10.21037/jtd-22-1292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745542/
https://www.ncbi.nlm.nih.gov/pubmed/36524068
http://dx.doi.org/10.21037/jtd-22-1292

Ejemplares similares